Wells Fargo’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-15,407
| Closed | -$24.5K | – | 7222 |
|
|
2024
Q1 | $24.5K | Buy |
15,407
+1,476
| +11% | +$2.35K | ﹤0.01% | 5136 |
|
|
2023
Q4 | $12K | Buy |
13,931
+2,651
| +24% | +$2.28K | ﹤0.01% | 5350 |
|
|
2023
Q3 | $12.1K | Sell |
11,280
-5,784
| -34% | -$6.19K | ﹤0.01% | 5385 |
|
|
2023
Q2 | $44.2K | Buy |
17,064
+9,021
| +112% | +$23.4K | ﹤0.01% | 5185 |
|
|
2023
Q1 | $32.8K | Buy |
8,043
+7,043
| +704% | +$28.7K | ﹤0.01% | 5093 |
|
|
2022
Q4 | $5.02K | Sell |
1,000
-459
| -31% | -$2.3K | ﹤0.01% | 5444 |
|
|
2022
Q3 | $19K | Sell |
1,459
-394
| -21% | -$5.13K | ﹤0.01% | 5113 |
|
|
2022
Q2 | $24K | Sell |
1,853
-10,819
| -85% | -$140K | ﹤0.01% | 5084 |
|
|
2022
Q1 | $193K | Sell |
12,672
-6,143
| -33% | -$93.6K | ﹤0.01% | 4696 |
|
|
2021
Q4 | $334K | Buy |
18,815
+523
| +3% | +$9.28K | ﹤0.01% | 4638 |
|
|
2021
Q3 | $384K | Sell |
18,292
-25,040
| -58% | -$526K | ﹤0.01% | 4545 |
|
|
2021
Q2 | $854K | Buy |
43,332
+27,531
| +174% | +$543K | ﹤0.01% | 4072 |
|
|
2021
Q1 | $460K | Sell |
15,801
-20,177
| -56% | -$587K | ﹤0.01% | 4429 |
|
|
2020
Q4 | $1.09M | Sell |
35,978
-15,135
| -30% | -$459K | ﹤0.01% | 3905 |
|
|
2020
Q3 | $813K | Sell |
51,113
-32,679
| -39% | -$520K | ﹤0.01% | 3920 |
|
|
2020
Q2 | $1.65M | Buy |
83,792
+46,661
| +126% | +$921K | ﹤0.01% | 3350 |
|
|
2020
Q1 | $458K | Buy |
37,131
+11,794
| +47% | +$145K | ﹤0.01% | 3981 |
|
|
2019
Q4 | $469K | Buy |
25,337
+21,917
| +641% | +$406K | ﹤0.01% | 4322 |
|
|
2019
Q3 | $47K | Buy |
3,420
+3,370
| +6,740% | +$46.3K | ﹤0.01% | 5284 |
|
|
2019
Q2 | $1K | Buy |
+50
| New | +$1K | ﹤0.01% | 5820 |
|